PLX7904

PLX7904 hinders the in vitro proliferation of two melanoma cell lines (A375 and COLO829) and an additional human colorectal cancer cell line COLO205 expressing BRAFV600E, with IC50 values of 0.17 μM, 0.53 μM, and 0.16 μM, respectively, comparable to the IC50 values of vemurafenib in the same assays (0.33 μM, 0.69 μM, and 0.25 μM, respectively)¹. PLX7904 and PLX8394 effectively suppress ERK1/2-driven GAL4-Elk1 reporter activity in PRT cells as well as parental cells. Treatment with PLX7904 and PLX8394 at a concentration of 1 μM reduces colony formation and viability in parental cells to a similar extent as PLX4720². PLX7904 strongly inhibits ERK1/2 phosphorylation in mutant BRAF melanoma cells without inducing paradoxical activation in wild-type BRAF or mutant NRAS melanoma cells. It also inhibits ERK1/2 in PLX470-resistant cell lines. Treatment with PLX7904 promotes apoptosis and suppresses anchorage-independent growth of vemurafenib-resistant cells³.

PLX7904 hinders the in vitro proliferation of two melanoma cell lines (A375 and COLO829) and an additional human colorectal cancer cell line COLO205 expressing BRAFV600E, with IC50 values of 0.17 μM, 0.53 μM, and 0.16 μM, respectively, comparable to the IC50 values of vemurafenib in the same assays (0.33 μM, 0.69 μM, and 0.25 μM, respectively)¹.

PLX7904 and PLX8394 effectively suppress ERK1/2-driven GAL4-Elk1 reporter activity in PRT cells as well as parental cells. Treatment with PLX7904 and PLX8394 at a concentration of 1 μM reduces colony formation and viability in parental cells to a similar extent as PLX4720².

PLX7904 strongly inhibits ERK1/2 phosphorylation in mutant BRAF melanoma cells without inducing paradoxical activation in wild-type BRAF or mutant NRAS melanoma cells. It also inhibits ERK1/2 in PLX470-resistant cell lines. Treatment with PLX7904 promotes apoptosis and suppresses anchorage-independent growth of vemurafenib-resistant cells³.

溶解方案(细胞实验)

DMSO 中的溶解度 : ≥ 30 mg/mL (58.53 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)|* "≥" means soluble, but saturation unknown.

溶解方案(动物实验)

"方案 一": "请依序添加每种溶剂：10% DMSO 40% PEG300 5% Tween-80 45% SalineSolubility: ≥ 2.5 mg/mL (4.88 mM); 澄清溶液 此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。"